Financial Performance - The basic earnings per share decreased by 10% to 1.53 yuan in 2024 from 1.70 yuan in 2023 [1] - The net asset per share increased by 59.63% to 7.71 yuan in 2024 from 4.83 yuan in 2023 [1] - The retained earnings per share rose by 14.83% to 3.33 yuan in 2024 from 2.90 yuan in 2023 [1] - The operating revenue slightly increased by 0.64% to 4.75 billion yuan in 2024 from 4.72 billion yuan in 2023 [1] - The net profit remained stable at 2.05 billion yuan in 2024 compared to 2.04 billion yuan in 2023, showing a 0.49% increase [1] - The return on equity significantly decreased by 43.17% to 24.29% in 2024 from 42.74% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 3.1724 million shares, accounting for 8.1% of the circulating shares, a decrease of 314,500 shares from the previous period [1] - New entrants among the top shareholders include Shenzhen Hanqingda Technology Co., Ltd. with 1.2833 million shares (3.27%) and several others [2] - Notable exits from the top shareholders include Barclays Bank PLC and Guotai Junan Securities Co., Ltd. [2][3] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share, with a total payout of 15 yuan (including tax) [4]
小方制药:2024年报净利润2.05亿 同比增长0.49%